Collectively, these findings suggest that genistein’s ability to inactivate NF-κB enhances cancer cell growth inhibition and apoptosis induced by cisplatin, docetaxel, and doxorubicin in prostate, breast, lung, and pancreatic cancers. Here, NFKB1 is linked to cancer.